00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
03:36 , Apr 18, 2019 |  BC Extra  |  Financial News

Hookipa raises $84M in IPO

Hookipa raised $84 million in an IPO on NASDAQ late Wednesday, pricing at the bottom of its range and selling fewer shares than the company had hoped. Hookipa Pharma Inc. (NASDAQ:HOOK) sold 6 million shares...
21:55 , Mar 22, 2019 |  BC Extra  |  Financial News

Hookipa proposes IPO as its cancer vaccines head towards the clinic

Infectious disease and cancer vaccine company Hookipa proposed Friday to raise up to $86.3 million in an IPO on NASDAQ. Hookipa Pharma Inc. (New York, N.Y.) is developing vaccines using its VaxWave and TheraT viral...
04:19 , Dec 15, 2018 |  BioCentury  |  Product Development

Extending Immunocore’s runway

The $100 million upfront payment from Immunocore Ltd.’s most recent deal with Roche's Genentech Inc. unit gives it enough cash to read out pivotal data from lead program IMCgp100, a catalyst that could help justify...
07:00 , Oct 26, 2015 |  BioCentury  |  Finance

Joining the in(novation) crowd

At least one buysider thinks the first two innovator Chinese biotechs to attempt a NASDAQ listing will be well-received by U.S. investors thanks to a combination of validating pharma deals and a stable of products...
07:00 , Sep 21, 2015 |  BioCentury  |  Finance

California raisin'

Mirati Therapeutics Inc. (NASDAQ:MRTX) has raised more money since moving to California and listing on NASDAQ about two years ago than the cancer company did in its prior 18 years of existence in Canada. On...
02:30 , May 7, 2015 |  BC Extra  |  Top Story

Alexion to acquire Synageva

Synageva BioPharma Corp. (NASDAQ:GEVA) soared $107.52 (112%) to $203.39 on news that Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) will acquire the company for $115 in cash and 0.6581 Alexion shares per Synageva share, or about $9 billion...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Financial News

Aquinox completes venture financing

Aquinox Pharmaceuticals Inc. , Vancouver, B.C.   Business: Cancer, Inflammation   Date completed: 4/3/13   Type: Venture financing   Raised: $18 million   Investors: Johnson & Johnson Development Corp.; Augment Investments; Pfizer Venture Investments; Ventures...
07:00 , Apr 8, 2013 |  BioCentury  |  Finance

PI3K party

PI3K party A group of VCs that includes several strategic investors provided Aquinox Pharmaceuticals Inc. with $18 million, which should carry it to the verge of Phase III testing for its second-generation inflammatory disease program...
23:32 , Apr 3, 2013 |  BC Extra  |  Financial News

Aquinox raises $18M in series C

Aquinox Pharmaceuticals Inc. (Vancouver, B.C.) raised US$18 million in a series C round led by existing investor Johnson & Johnson Development Corp. New investor Augment Investments also participated, along with existing investors Pfizer Venture Investments;...